Search
GLB-001
go.drugbank.com/drugs/DB32795InvestigationalGLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).
Tiapride
go.drugbank.com/drugs/DB13025InvestigationalTiapride is a selective D2 and D3 dopamine receptor blocker in the brain.
ING-1
go.drugbank.com/drugs/DB05831InvestigationalING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractiv...
Carotuximab
go.drugbank.com/drugs/DB06322InvestigationalSynonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER, GAMMA1 HEAVY CHAIN (1-448) (MUS MUSCULUS VH (IGHV6-6*01-(IGHD) -IGHJ2*01) (8.10.9) (1-118) -HOMO SAPIENSIGHG1*01, GM17,1 (CH1 (119-216), HINGE (217-231), CH2(232-341), CH3 (342-446), CHS (447-448)) (119Zosuquidar
go.drugbank.com/drugs/DB06191InvestigationalZosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with t...
MUC1 Dendritic Cell Vaccine
go.drugbank.com/drugs/DB05477InvestigationalThese cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalHGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Tasosartan
go.drugbank.com/drugs/DB01349ExperimentalTasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Filanesib
go.drugbank.com/drugs/DB06040InvestigationalFilanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
SARS-CoV-2 Sclamp
go.drugbank.com/drugs/DB15849InvestigationalAs of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932).